Arcturus Therapeutics Holdings Inc. (ARCT): Price and Financial Metrics
ARCT Price/Volume Stats
| Current price | $24.94 | 52-week high | $37.75 |
| Prev. close | $24.49 | 52-week low | $13.83 |
| Day low | $24.37 | Volume | 66,026 |
| Day high | $25.29 | Avg. volume | 439,854 |
| 50-day MA | $29.84 | Dividend yield | N/A |
| 200-day MA | $24.95 | Market Cap | 663.38M |
ARCT Stock Price Chart Interactive Chart >
ARCT POWR Grades
- ARCT scores best on the Value dimension, with a Value rank ahead of 99.06% of US stocks.
- The strongest trend for ARCT is in Growth, which has been heading down over the past 177 days.
- ARCT's current lowest rank is in the Growth metric (where it is better than 1.31% of US stocks).
ARCT Stock Summary
- Of note is the ratio of ARCTURUS THERAPEUTICS HOLDINGS INC's sales and general administrative expense to its total operating expenses; just 9.54% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of -70.4%, ARCTURUS THERAPEUTICS HOLDINGS INC's debt growth rate surpasses just 2.94% of about US stocks.
- Revenue growth over the past 12 months for ARCTURUS THERAPEUTICS HOLDINGS INC comes in at 551.91%, a number that bests 98.97% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to ARCTURUS THERAPEUTICS HOLDINGS INC are VIR, ENTA, RNA, CCCC, and TSVT.
- ARCT's SEC filings can be seen here. And to visit ARCTURUS THERAPEUTICS HOLDINGS INC's official web site, go to www.arcturusrx.com.
ARCT Valuation Summary
- In comparison to the median Healthcare stock, ARCT's price/sales ratio is 32.5% lower, now standing at 2.7.
- Over the past 121 months, ARCT's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ARCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARCT | 2023-09-22 | 2.7 | 2.5 | 9.0 | 4.9 |
| ARCT | 2023-09-21 | 2.7 | 2.5 | 8.9 | 4.8 |
| ARCT | 2023-09-20 | 2.7 | 2.5 | 8.8 | 4.7 |
| ARCT | 2023-09-19 | 2.8 | 2.6 | 9.2 | 5.2 |
| ARCT | 2023-09-18 | 2.7 | 2.5 | 9.0 | 4.9 |
| ARCT | 2023-09-15 | 2.9 | 2.7 | 9.5 | 5.4 |
ARCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARCT has a Quality Grade of D, ranking ahead of 24% of graded US stocks.
- ARCT's asset turnover comes in at 0.02 -- ranking 368th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ARCT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.020 | 1 | -32.552 |
| 2021-03-31 | 0.025 | 1 | -19.685 |
| 2020-12-31 | 0.037 | 1 | -30.242 |
| 2020-09-30 | 0.066 | 1 | -5.591 |
| 2020-06-30 | 0.115 | 1 | -4.145 |
| 2020-03-31 | 0.244 | 1 | -2.814 |
ARCT Price Target
For more insight on analysts targets of ARCT, see our ARCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $78.46 | Average Broker Recommendation | 1.88 (Hold) |
Arcturus Therapeutics Holdings Inc. (ARCT) Company Bio
Arcturus Therapeutics Ltd a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company was founded in 2008 and is based in Tel Aviv, Israel.
Latest ARCT News From Around the Web
Below are the latest news stories about ARCTURUS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ARCT as an investment opportunity.
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic FibrosisSAN DIEGO, September 26, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, announced today that Arcturus and the Cystic Fibrosis Foundation (CF Foundation) have extended their ongoing agreement. The CF Foundation agreed to increase its financial commitment to ~$25 million to advance |
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 VariantsSAN DIEGO, September 19, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the results of a phase 1/2 study showing that a booster dose of a novel, self-amplifying messenger RNA (sa-mRNA) vaccine against COVID-19 induces a robust, broadly cross-reactive, and durable i |
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19SAN DIEGO, September 05, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, and CSL (ASX:CSL), and its vaccine business, CSL Seqirus, one of the largest influenza vaccine providers in the world, announced today that the European Medicines Agency (EMA) has validated the marketing autho |
Arcturus Therapeutics to Attend Upcoming Investor ConferencesSAN DIEGO, August 17, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: |
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese GovernmentSAN DIEGO, August 14, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that ARCALIS Co., Ltd., its manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been awarded $115 million in two separate grants from the Japanese |
ARCT Price Returns
| 1-mo | N/A |
| 3-mo | -14.24% |
| 6-mo | N/A |
| 1-year | 49.07% |
| 3-year | -41.72% |
| 5-year | 215.70% |
| YTD | 47.05% |
| 2022 | -54.17% |
| 2021 | -14.68% |
| 2020 | 299.08% |
| 2019 | 139.96% |
| 2018 | -43.02% |
Loading social stream, please wait...